These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35963006)

  • 1. EFFECT OF PHYSICIAN FACE MASK USE ON POSTINJECTION ENDOPHTHALMITIS.
    Fortes BH; Astafurov KV; Hodge DO; Smith WM; Barkmeier AJ; Olsen TW; Iezzi R; Bakri SJ
    Retina; 2022 Nov; 42(11):2120-2127. PubMed ID: 35963006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Physician Face Mask Use on Endophthalmitis After Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Patel SN; Hsu J; Sivalingam MD; Chiang A; Kaiser RS; Mehta S; Park CH; Regillo CD; Sivalingam A; Vander JF; Ho AC; Garg SJ;
    Am J Ophthalmol; 2021 Feb; 222():194-201. PubMed ID: 32888902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Influence of Universal Face Mask Use on Endophthalmitis Risk after Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    ; Patel SN; Tang PH; Storey PP; Wolfe JD; Fein J; Shah SP; Chen E; Abbey A; Ferrone PJ; Shah CP; Liang MC; Stem MS; Ali Khan M; Yonekawa Y; Garg SJ
    Ophthalmology; 2021 Nov; 128(11):1620-1626. PubMed ID: 34019955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Legal obligation in the general population: face mask influence on endophthalmitis after intravitreal injection.
    Neubauer J; Gklavas K; Kortüm F; Gosheva M; Bartz-Schmidt KU; Ziemssen F
    Graefes Arch Clin Exp Ophthalmol; 2023 Jan; 261(1):97-102. PubMed ID: 35932321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of patient face mask use on endophthalmitis after intravitreal anti-VEGF injections.
    Hébert M; You E; Hammamji K; Bourgault S; Caissie M; Tourville É; Dirani A
    Can J Ophthalmol; 2022 Dec; 57(6):364-369. PubMed ID: 34419421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Prefilled Syringes on Endophthalmitis Following Intravitreal Injection of Ranibizumab.
    Storey PP; Tauqeer Z; Yonekawa Y; Todorich B; Wolfe JD; Shah SP; Shah AR; Koto T; Abbey AM; Morizane Y; Sharma P; Wood EH; Morizane-Hosokawa M; Pendri P; Pancholy M; Harkey S; Jeng-Miller KW; Obeid A; Borkar DS; Chen E; Williams P; Okada AA; Inoue M; Shiraga F; Hirakata A; Shah CP; Prenner J; Garg S;
    Am J Ophthalmol; 2019 Mar; 199():200-208. PubMed ID: 30552891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Pandemic Is Not Associated with Endophthalmitis Decrease after Anti-Vascular Endothelial Growth Factor Injections.
    Lum F; Li S; Liu L; Li C; Parke DW; Williams GA
    Ophthalmology; 2022 Jun; 129(6):719-721. PubMed ID: 35041903
    [No Abstract]   [Full Text] [Related]  

  • 8. Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.
    Rayess N; Rahimy E; Storey P; Shah CP; Wolfe JD; Chen E; DeCroos FC; Garg SJ; Hsu J
    Am J Ophthalmol; 2016 May; 165():88-93. PubMed ID: 26944277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT).
    Meredith TA; McCannel CA; Barr C; Doft BH; Peskin E; Maguire MG; Martin DF; Prenner JL;
    Ophthalmology; 2015 Apr; 122(4):817-21. PubMed ID: 25600198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Writing committee for the Post-Injection Endophthalmitis Study Group, et al.: The influence of universal face mask use on endophthalmitis risk after intravitreal anti-vascular endothelial growth factor injections (Ophthalmology. 2021;128:1620-1626).
    Blom K; Bragadóttir R; Sivertsen MS; Moe MC; Jørstad ØK
    Ophthalmology; 2022 May; 129(5):e61-e62. PubMed ID: 35232584
    [No Abstract]   [Full Text] [Related]  

  • 11. Endophthalmitis after Anti-VEGF Intravitreal Injections with Aqueous Chlorhexidine versus Povidone-Iodine as Ocular Antiseptics.
    Ton NS; Goncharov V; Zapata I; Adam MK
    Ophthalmol Retina; 2024 Jun; 8(6):521-526. PubMed ID: 38122867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask.
    Shimada H; Hattori T; Mori R; Nakashizuka H; Fujita K; Yuzawa M
    Graefes Arch Clin Exp Ophthalmol; 2013 Aug; 251(8):1885-90. PubMed ID: 23389553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NO EFFECT OF REAL-WORLD UNIVERSAL FACE MASKING ON POST-INTRAVITREAL INJECTION ENDOPHTHALMITIS RATE AT A SINGLE TERTIARY ACADEMIC CENTER.
    Haliyur R; Sinha AK; Andrews CA; Musch DC; Conrady CD; Zacks DN; Huvard MJ
    Retina; 2024 May; 44(5):916-922. PubMed ID: 38207176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of endophthalmitis rates following intravitreal injection of compounded bevacizumab, ranibizumab, and aflibercept.
    Forooghian F; Albiani DA; Kirker AW; Merkur AB
    Can J Ophthalmol; 2017 Dec; 52(6):616-619. PubMed ID: 29217032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-intravitreal injection endophthalmitis pattern during the COVID-19 pandemic with implementation of patients' masking.
    Mirghorbani M; Bazvand F; Riazi-Esfahani H; Bahar MM; Yaseri M; Zarei M
    Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3657-3664. PubMed ID: 35678839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTIONS DURING THE COVID-19 PANDEMIC WITH IMPLEMENTATION OF UNIVERSAL MASKING.
    Naguib MM; Ghauri S; Mukhopadhyay A; Schefler AC
    Retina; 2021 Nov; 41(11):2208-2214. PubMed ID: 33958531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endophthalmitis following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy: Changes in Incidence and Outcomes over a 9-Year Period.
    Pancholy M; Storey PP; Levin HJ; Obeid A; Patel SN; Kuley B; Hsu J; Spirn MJ; Fineman M; Klufas MA; Gupta O; Ho AC; Garg SJ
    Curr Eye Res; 2021 Sep; 46(9):1370-1377. PubMed ID: 33522314
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravitreal injections at the Massachusetts Eye and Ear Infirmary: analysis of treatment indications and postinjection endophthalmitis rates.
    Englander M; Chen TC; Paschalis EI; Miller JW; Kim IK
    Br J Ophthalmol; 2013 Apr; 97(4):460-5. PubMed ID: 23390167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment.
    Gregori NZ; Flynn HW; Schwartz SG; Rosenfeld PJ; Vaziri K; Moshfeghi AA; Fortun JA; Kovach JL; Dubovy SR; Albini TA; Davis JL; Berrocal AM; Smiddy WE
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):643-8. PubMed ID: 26114845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of compounded bevacizumab with postinjection endophthalmitis.
    VanderBeek BL; Bonaffini SG; Ma L
    JAMA Ophthalmol; 2015 Oct; 133(10):1159-64. PubMed ID: 26270251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.